Healthcare Industry News: esophageal cancer
News Release - December 2, 2016
CSA Medical Announces First Use of Significantly Reduced Diameter Cryogen Decompression Tube in a truFreeze(R) Spray Cryotherapy CaseLEXINGTON, Mass., Dec. 1, 2016 -- (Healthcare Sales & Marketing Network) -- CSA Medical today announced the initial use of a modified cryogen decompression tube (CDT) during a truFreeze Spray Cryotherapy (SCT) case at Dartmouth-Hitchcock Medical Center. Dr. Stuart Gordon utilized the new CDT, which has a 35% reduction in cross-sectional area, in a patient undergoing SCT ablation for local esophageal cancer. During the application of SCT in the gastrointestinal tract the conversion of liquid nitrogen, the most powerful cryogen currently available for medical use, into nitrogen gas requires evacuation of that gas from organs distal to the treatment site. The CDT provides that decompression. CSA notes that this product launch is the first in a series of product updates anticipated by the company for the truFreeze franchise over the next two quarters.
"We have heard from our physician users the desire to provide SCT to more patients suffering from local persistence of esophageal cancer but their bulky disease prevents passage of the CDT. Thus we have developed a CDT that addresses this anatomical restriction by providing a 35% reduction in cross-sectional area with the same decompression ability as its predecessor. The reduced diameter will allow physicians to provide SCT to many more patients in need of this therapy while maintaining the same safety provisions provided by the CDT. Our ongoing commitment to enhancing our physician users experience with SCT in their medical practices will result in other product enhancements in the coming year," states Ellen Sheets, MD, CEO CSA Medical.
After using the reduced diameter CDT, Dr. Gordon, Director, Gastrointestinal Endoscopy, Associate Professor of Medicine, Geisel School of Medicine, Dartmouth stated that the new CDT has a "noticeably small caliber which makes it more easily passed than the prior CDT, especially with the presence of stenotic tumor burden."
CSA Medical anticipates that the smaller diameter CDT will enter full market release in Q2 2017.
About CSA Medical
CSA Medical, Inc. develops and manufactures a proprietary interventional spray cryotherapy technology platform utilizing unique properties of liquid nitrogen spray delivered by a software driven device with specialty catheters that enable delivery of spray cryogen inside the body to flash freeze and destroy unwanted tissue allowing for a rejuvenative pattern of healing. CSA manufactures and distributes this technology in the USA as the truFreezeŽ system which is currently used to ablate unwanted benign and malignant tissue.
To learn more about our technology, please visit http://csamedical.com/.
truFreeze is a registered trademark of CSA Medical, Inc.
Source: CSA Medical
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.